Drug Trial Radar · NCT03833180
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)
Last checked: Nov 19, 2026Latest source record: Jan 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
91
Actual
Start
Mar 14, 2019
Primary completion
Dec 18, 2023
Study completion Dec 18, 2023
Sponsor
- Lead sponsor
- VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Industry
- Sponsor type
- Industry
- First posted
- Feb 6, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, pharmacokinetics, immunogenicity, and efficacy of zilovertamab vedotin given intravenously (IV) across a range of dose levels in participants with previously treated hematological cancers including acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), Burkitt lymphoma (BL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), lymphoplasmacytoid lymphoma/Waldenström macroglobulinemia (LPL/WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), Richter transformation lymphoma (RTL), and T-cell non-Hodgkin lymphoma (NHL).
Conditions
- Chronic Lymphocytic Leukemia
- Mantle Cell Lymphoma
- Follicular Lymphoma
- Marginal Zone Lymphoma
- Diffuse Large B-cell Lymphoma
- Richter Transformation Lymphoma
- Burkitt Lymphoma
- Lymphoplasmacytoid Lymphoma
- T-cell Non-Hodgkin Lymphoma
- Acute Lymphoid Leukemia
- Acute Myeloid Leukemia
- Waldenstrom Macroglobulinemia
Interventions
Zilovertamab vedotinDrug
Zilovertamab vedotin administered via IV infusion per Schedule 1, 2, or 3 according to participant allocation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum tolerated dose (MTD) of zilovertamab vedotinTime frame: Cycle 1 (Up to 21 Days)
- Recommended Dosing Regimen (RDR)Time frame: Cycle 1 (Up to 21 Days)
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
City of Hope ( Site 0010)
Duarte, California
University of California - San Diego ( Site 0003)
La Jolla, California
UCLA Hematology & Oncology ( Site 0007)
Los Angeles, California
University of Nebraska Medical Center ( Site 0006)
Omaha, Nebraska
Northwell Health ( Site 0009)
New Hyde Park, New York
Weill Cornell Medical College ( Site 0005)
New York, New York
Memorial Sloan Kettering Cancer Center ( Site 0014)
New York, New York
University of Rochester ( Site 0008)
Rochester, New York
Memorial Sloan-Kettering Cancer Center ( Site 0019)
Uniondale, New York
Oregon Health & Science University ( Site 0004)
Portland, Oregon
MD Anderson Cancer Center ( Site 0001)
Houston, Texas
MD Anderson Cancer Center ( Site 0011)
Houston, Texas
University of Virginia Cancer Center ( Site 0012)
Charlottesville, Virginia
Swedish Medical Center ( Site 0002)
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.